13 research outputs found
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis
Topic This study evaluated the cardiovascular/cerebrovascular safety profile of ranibizumab 0.5 mg versus sham ± verteporfin in patients with neovascular age-related macular degeneration (nAMD). In addition, comparisons of ranibizumab 0.3 mg with sham and ranibizumab 0.5 mg to 0.3 mg were performed. Clinical Relevance Intravitreal anti–vascular endothelial growth factor (VEGF) agents carry potential increased systemic risks, including cardiovascular or cerebrovascular events. Pooled safety analyses allow better interpretation of safety outcomes seen in individual clinical trials, especially for less common events. To our knowledge, this is the largest patient-level pooled analysis of patients with nAMD treated with ranibizumab. Methods Patient-level pooled analysis of data from 7 Genentech- and Novartis-sponsored phase II, III, and IV studies in nAMD that were completed by December 31, 2013. Pairwise comparisons (primary comparison: ranibizumab 0.5 mg [globally approved dose for nAMD] vs. sham or verteporfin) were performed using Cox proportional hazard regression (hazard ratios [HRs], 95% confidence intervals [CIs]) and rates per 100 patient-years. Standardized Medical Dictionary for Regulatory Activities queries (SMQs) and extended searches were used to identify relevant safety endpoints, including arterial thromboembolic events (ATEs), myocardial infarction (MI), stroke or transient ischemic attack (TIA), stroke (excluding TIA), vascular deaths, and major vascular events as defined by the Antiplatelet Trialists' Collaboration (APTC). Results The HRs (95% CIs) for the primary comparison of ranibizumab 0.5 mg (n=480) versus sham or verteporfin (n=462) were 1.16 (0.72–1.88) for ATE, 1.33 (0.59–2.97) for MI, 1.43 (0.54–3.77) for stroke excluding TIA, 1.25 (0.61–2.55) for stroke or TIA, 0.57 (0.18–1.78) for vascular death, and 1.12 (0.64–1.98) for APTC events. Hazard ratio 95% CIs included 1, indicating no significant treatment differences, for all endpoints for comparison of ranibizumab 0.5 mg versus sham or verteporfin. Conclusions The rates of cardiovascular and cerebrovascular events were low in these patients with nAMD and not clinically meaningfully different for patients treated with ranibizumab 0.5 mg versus sham or verteporfin, which supports the favorable benefit–risk profile of ranibizumab in the patient population with nAMD. Pooling these studies allows an analysis with higher power and precision compared with individual study analyses
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Analyses of adverse events (AEs) are an important aspect of the evaluation of
experimental therapies. The SAVVY (Survival analysis for AdVerse events with
Varying follow-up times) project aims to improve the analyses of AE data in
clinical trials through the use of survival techniques appropriately dealing
with varying follow-up times, censoring, and competing events (CE). In an
empirical study including seventeen randomized clinical trials the effect of
varying follow-up times, censoring, and competing events on comparisons of two
treatment arms with respect to AE risks is investigated. The comparisons of
relative risks (RR) of standard probability-based estimators to the
gold-standard Aalen-Johansen estimator or hazard-based estimators to an
estimated hazard ratio (HR) from Cox regression are done descriptively, with
graphical displays, and using a random effects meta-analysis on AE level. The
influence of different factors on the size of the bias is investigated in a
meta-regression. We find that for both, avoiding bias and categorization of
evidence with respect to treatment effect on AE risk into categories, the
choice of the estimator is key and more important than features of the
underlying data such as percentage of censoring, CEs, amount of follow-up, or
value of the gold-standard RR. There is an urgent need to improve the
guidelines of reporting AEs so that incidence proportions are finally replaced
by the Aalen-Johansen estimator - rather than by Kaplan-Meier - with
appropriate definition of CEs. For RRs based on hazards, the HR based on Cox
regression has better properties than the ratio of incidence densities
Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs.
To support informed decision making, clear descriptions of the beneficial and harmful effects of a treatment are needed by various stakeholders. The current paradigm is to generate evidence sequentially through different experiments. However, data generated later, perhaps through observational studies, can be difficult to compare with earlier randomized trial data, resulting in confusion in understanding and interpretation of treatment effects. Moreover, the scientific questions these later experiments can serve to answer often remain vague. We propose Flexible Augmented Clinical Trial for Improved eVidence gEneration (FACTIVE), a new class of study designs enabling flexible augmentation of confirmatory randomized controlled trials with concurrent and close-to-real-world elements. Our starting point is to use clearly defined objectives for evidence generation, which are formulated through early discussion with health technology assessment (HTA) bodies and are additional to regulatory requirements for authorization of a new treatment. These enabling designs facilitate estimation of certain well-defined treatment effects in the confirmatory part and other complementary treatment effects in a concurrent real-world part. Each stakeholder should use the evidence that is relevant within their own decision-making framework. High quality data are generated under one single protocol and the use of randomization ensures rigorous statistical inference and interpretation within and between the different parts of the experiment. Evidence for the decision making of HTA bodies could be available earlier than is currently the case
Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study
Objective!#!To evaluate the effectiveness, treatment patterns and long-term safety of ranibizumab 0.5 mg in treatment-naïve patients with central retinal vein occlusion (CRVO) in a real-world setting.!##!Methods!#!LUMINOUS, a 5-year, global, prospective, multicentre, multi-indication, observational, open-label study, recruited treatment naïve or prior treated patients who were treated as per the local ranibizumab label. Here, we report the mean change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters), treatment exposure over year (Y) 1 and 5-year safety in treatment-naïve CRVO patients.!##!Results!#!At baseline, the mean age of treatment-naïve CRVO patients (n = 327) was 68.9 years, with a mean (Standard deviation [SD]) VA of 40.6 (23.9) letters. At Y1, patients (n = 144) had a mean (SD) VA gain from baseline of 10.8 (19.66) letters, with a mean (SD) of 5.4 (2.65) ranibizumab injections. Patients demonstrated mean (SD) VA gains of 2.7 (19.35), 11.6 (20.56), 13.9 (18.08), 11.1 (18.46) and 8.2 (24.86) letters with 1, 2-3, 4-5, 6-8 and >8 ranibizumab injections, respectively. Mean (SD) VA gains at Y1 in patients receiving loading (67.4%) and no loading dose (32.6%) was 11.9 (20.42) and 8.4 (17.99) letters, respectively. Over five years, the incidence of ocular/non-ocular adverse events (AEs) and serious AEs was 11.3%/8.6% and 1.2%/6.7%, respectively.!##!Conclusions!#!These results demonstrate the effectiveness of ranibizumab in treatment-naïve CRVO patients at Y1 with clinically meaningful VA gains and no new safety findings over five years. These findings may help inform routine practice and enable better clinical management to achieve optimal visual outcomes
Do you want to stay single? Considerations on single arm trials in drug development and the post-regulatory space
Single arm trials (SAT), while not preferred, remain in use throughout the drug development cycle. They may be accepted by regulators in particular contexts (eg., oncology and in rare diseases) when potential effects of new treatments are very large and placebo treatment is unethical. However, in the post-regulatory space, SATs are common, and perhaps even more poorly suited to address the questions of interest. In this manuscript, we review regulator and HTA positions on SATs, further challenges posed by SATs to address research questions beyond regulators, evolving statistical methods to provide context for SATs, case studies where SATs could and could not address questions or interest, and communication strategies to influence decision making and optimize study design to address evidence needs
Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\uefve patients with diabetic macular edema: Results from the real-world global LUMINOUS study
Purpose
To assess the one-year effectiveness and safety of ranibizumab 0.5 mg in treatment- na\uefve
patients with diabetic macular edema (DME) enrolled in the real-world LUMINOUS study.
Patients and methods
A 5-year, prospective, observational, open-label, global study which recruited 30,138
patients across all approved indications. Consenting patients (\ufffd18 years) who were treatment-
na\uefve or previously treated with ranibizumab or other ocular treatments were treated
as per the local ranibizumab label. Here, we present the change in visual acuity (VA) (Early
Treatment Diabetic Retinopathy Study letter score; primary treated eye) at Year 1, as well
as the change in VA based on injection frequencies (\ufffd4 and \ufffd5), treatment exposure, and
the overall adverse events (AEs) and serious AEs (SAEs) in treatment-na\uefve DME patients.
Results
Of the 4,710 DME patients enrolled in the study, 1,063 were treatment-na\uefve. At baseline,
mean age was 64.5 years, 54.7% were male, and 69.2% were white. At 1 year, mean VA letter
score improved by +3.5 (n = 502) from a baseline of 57.7 with a mean of 4.5 injections.Presented by injection frequencies \ufffd4 and \ufffd5, VA letter score gains were 0.5 (n = 264) and
6.9 (n = 238) from baseline letter scores of 56.6 and 59.0, respectively. Over 5 years, the
incidence of ocular/non-ocular AEs and SAEs was 7.2%/10.1% and 0.3%/5.8%, respectively.
No endophthalmitis cases were reported.
Conclusions
The LUMINOUS study included patients with DME with more diverse baseline characteristics
than those in randomized clinical trials. The 1-year data showed improvement in VA with
low number of injections in treatment- na\uefve patients with DME. Greater VA gains were
observed in patients who received \ufffd5 injections. No new safety findings were identified.
LUMINOUS confirms the effectiveness and safety of ranibizumab for the treatment of
patients with DME in a real-world clinical practice